Literature DB >> 14976004

Signaling in leukocyte transendothelial migration.

Jaap D van Buul1, Peter L Hordijk.   

Abstract

Under a variety of (patho) physiological conditions, leukocytes will leave the bloodstream by crossing the endothelial monolayer that lines the vessels and migrate into the underlying tissues. It is now clear that the process of extravasation involves a range of adhesion molecules on both leukocytes and endothelial cells, as well as extensive intracellular signaling that drives adhesion and chemotaxis on the one hand and controls a transient modulation of endothelial integrity on the other. We review here the current knowledge of the intracellular signaling pathways that are activated in the context of transendothelial migration in leukocytes and in endothelial cells. In leukocytes, polarization of receptors and of the signaling machinery is of key importance to drive adhesion and directional migration. Subsequent adhesion-induced signaling in endothelial cells, mediated by Rho-like GTPases and reactive oxygen species, induces a transient and focal loss of endothelial cell-cell adhesion to allow transmigration of the leukocyte. This review underscores the notion that we have likely just scratched the surface in revealing the complexity of the signaling that controls leukocyte transendothelial migration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14976004     DOI: 10.1161/01.ATV.0000122854.76267.5c

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  49 in total

Review 1.  Recent insights into endothelial control of leukocyte extravasation.

Authors:  Peter L Hordijk
Journal:  Cell Mol Life Sci       Date:  2016-01-21       Impact factor: 9.261

Review 2.  Rho GTPases and leucocyte-induced endothelial remodelling.

Authors:  Jaime Millán; Anne J Ridley
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

Review 3.  Blood-brain barrier: structural components and function under physiologic and pathologic conditions.

Authors:  Yuri Persidsky; Servio H Ramirez; James Haorah; Georgette D Kanmogne
Journal:  J Neuroimmune Pharmacol       Date:  2006-07-06       Impact factor: 4.147

4.  Differential changes in junctional complex proteins suggest the ependymal lining as the main source of leukocyte infiltration into ventricles in murine neurocysticercosis.

Authors:  Jorge I Alvarez; Judy M Teale
Journal:  J Neuroimmunol       Date:  2007-06-26       Impact factor: 3.478

5.  Transmigration across activated endothelium induces transcriptional changes, inhibits apoptosis, and decreases antimicrobial protein expression in human monocytes.

Authors:  Marcie R Williams; Yumiko Sakurai; Susu M Zughaier; Suzanne G Eskin; Larry V McIntire
Journal:  J Leukoc Biol       Date:  2009-08-25       Impact factor: 4.962

6.  Fractalkine receptor polymorphism may not be associated with the development and clinical course of ulcerative colitis.

Authors:  Hale Gokcan; Erkan Yurtcu; Haldun Selcuk; Feride I Sahin
Journal:  Bosn J Basic Med Sci       Date:  2015-05-25       Impact factor: 3.363

7.  PI3K is involved in β1 integrin clustering by PSGL-1 and promotes β1 integrin-mediated Jurkat cell adhesion to fibronectin.

Authors:  Jixian Luo; Chunfeng Li; Tingshuang Xu; Wenai Liu; Xueqing Ba; Xiaoguang Wang; Xianlu Zeng
Journal:  Mol Cell Biochem       Date:  2014-01       Impact factor: 3.396

8.  PI3K Is a Linker Between L-selectin and PSGL-1 Signaling to IL-18 Transcriptional Activation at the Promoter Level.

Authors:  Jixian Luo
Journal:  Inflammation       Date:  2018-03       Impact factor: 4.092

9.  New specific molecular targets for radio-chemotherapy of rectal cancer.

Authors:  Kristin Snipstad; Christopher G Fenton; Jørn Kjaeve; Guanglin Cui; Endre Anderssen; Ruth H Paulssen
Journal:  Mol Oncol       Date:  2009-11-25       Impact factor: 6.603

10.  In vitro cell migration and invasion assays.

Authors:  Calvin R Justus; Nancy Leffler; Maria Ruiz-Echevarria; Li V Yang
Journal:  J Vis Exp       Date:  2014-06-01       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.